You are here: Industry Insights > Everest Medicines

News List

Everest Medicines Initiates Submission of New Drug Application in Hong Kong, S.A.R., China for XeravaTM for the Treatment of Complicated Intra-abdominal Infections prnasia
October 13, 2021
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206 prnasia
September 28, 2021
Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia...
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies prnasia
September 28, 2021
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement...
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent prnasia
July 12, 2021
Everest Medicines announced that it has entered into a strategic commercial partnership with Tencent, one of the world's largest technology companies, to explore novel ways to optimize meaningful digital engagement with patients and healthcare providers.
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 21, 2021
Everest Medicines announced that sacituzumab govitecan-hziy (SG) was granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 06, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea ...
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited prnasia
March 01, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the ...
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer prnasia
January 07, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that it has ...
Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer prnasia
January 07, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that the Center ...
First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy for Breast Cancer americanpharmaceuticalreview
December 30, 2020
Everest Medicines announced the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal ...

Previous page 1 2 3 Next page